Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + lenvatinib + pembrolizumab neoadjuvant therapy vs upfront surgery in resectable BCLC C hepatocellular carcinoma
ChiCTR2300073434Phase 3Not yet recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Jul 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of pembrolizumab, lenvatinib, oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: 3-year overall survival rate. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300073434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073434.